Understanding the Changing Treatment Landscape of Severe Asthma is organized by Healio, National Jewish Health (NJH)
Release Date: November 28, 2023
Expiration Date: November 28, 2024
Activity Description:
The discovery of the mechanisms of type 2 (T2) inflammation in asthma gave rise to biological therapies that have dramatically expanded treatment options for patients with moderate-to-severe eosinophilic or allergic asthma. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes.
In this activity, expert faculty will provide insights into the new paradigm of treatments and how to manage the complexity of severe asthma treatment. This program will focus on the role of epithelial alarmins in the inflammatory cascade of asthma, and connecting clinical characteristics to patients’ biomarkers for treatment. Topics include current challenges in severe asthma management; the pathophysiology of severe asthma; targets for current and emerging treatments; and selecting treatments based on patient phenotypes.
Learning Objectives:
• Explain the mechanisms of action of biological therapies for severe asthma and key features of severe asthma that are targets for treatment.
• Describe the role of the respiratory epithelium in asthma and the relationship to T2 and non-T2 airway inflammation.
• Evaluate the emerging data for new and emerging therapies that target the epithelial alarmins.
• Connect clinical characteristics and phenotypes to the targeted treatment.